{{header
 | author     = Joseph R. Pitts
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2014
 | month      = 03
 | day        = 26
 | notes      = ''{{USBill|113|H.R.|4299}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 2
 | title      = Improving Regulatory Transparency for New Medical Therapies Act ( H.R. 4299; 113th Congress)
 | bill       = 4299
 | billtype   = hr
 | purpose    = To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.
 | wikipedia  =
}}
      
{{Center|113th CONGRESS}}

 
{{Center|2d Session}}

 
{{Center|H. R. 4299}}

 
{{Center|IN THE HOUSE OF REPRESENTATIVES}}

  
{{Center|March 26, 2014}}

 
{{Center| 
[[w:Joseph R. Pitts|Mr. Pitts]](for himself and
[[w:Frank Pallone|Mr. Pallone]]) introduced the following bill; which was referred to the [[w:United States House Committee on Energy and Commerce|Committee on Energy and Commerce]], and in addition to the [[w:United States House Committee on the Judiciary|Committee on the Judiciary]], for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned}}

  
{{Center|A BILL}}

 To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.   

=Section 1. Short title=

This Act may be cited as the“   Improving Regulatory Transparency for New Medical Therapies Act   ”. 

=Sec. 2. Scheduling of substances included in new FDA-approved drugs=

   Section 201 of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/811 21 U.S.C. 811] )is amended by inserting after subsection (h) the following:

<blockquote> 
:(i) Within 45 days of receiving a recommendation from the [[w:Department of Health and Human Services|Secretary]]to add a drug or substance that has never been marketed in the United States to a schedule under this title, the [[w:United States Department of Justice|Attorney General]]shall, without regard to the findings required by subsection (a) of this section or section 202(b) , issue an interim final rule, under the exception for good cause described in[http://www.law.cornell.edu/uscode/text/5/553 subparagraph (B) ofsection 553(b)of title 5, United States Code], placing the drug or substance into the schedule recommended by the [[w:Department of Health and Human Services|Secretary]]. The interim final rule shall be made immediately effective under[http://www.law.cornell.edu/uscode/text/5/553 section 553(d)(3) of title 5, United States Code]. . 
</blockquote>
 

=Sec. 3. Enhancing new drug development=

   Section 302 of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/822 21 U.S.C. 822] )is amended by inserting after subsection (g) the following:

<blockquote> 
:(h) 
::(1) A person who submits an application for registration to manufacture or distribute a controlled substance in accordance with this section may indicate on the registration application that the substance will be used only in connection with clinical trials of a drug in accordance with section 505(i) of the Federal Food, Drug, and Cosmetic Act .
::(2) When an application for registration to manufacture or distribute a controlled substance includes an indication that the controlled substance will be used only in connection with clinical trials of a drug in accordance with section 505(i) of the Federal Food, Drug, and Cosmetic Act , the [[w:United States Department of Justice|Attorney General]]shall—
:::(A) make a final decision on the application for registration within 180 days; or
:::(B) provide notice to the applicant in writing of—
::::(i) the outstanding issues that must be resolved in order to reach a final decision on the application; and
::::(ii) the estimated date on which a final decision on the application will be made. . 
</blockquote>
  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
